Immix Biopharma, Inc. Announces Amendment to At The Market Offering Agreement with Citizens JMP Securities, LLC

LOS ANGELES, March 25, 2026 — Immix Biopharma, Inc. (NASDAQ: IMMX), a clinical-stage biopharmaceutical company, has announced a significant update to its capital markets strategy. The company entered into Amendment No. 1 to its existing At The Market (“ATM”) Offering Agreement with Citizens JMP Securities, LLC, originally dated June 3, 2025.

Key Highlights of the Announcement

• Material Definitive Agreement: The amendment modifies the terms under which Immix Biopharma may sell its common stock, par value \$0.0001 per share, from time to time through Citizens JMP Securities, LLC as sales agent.
• Flexibility in Capital Raising: The company retains the option to offer and sell shares at its discretion, subject to market conditions and parameters it sets, including price, timing, and size.
• Sales Limitations: The amendment ensures that share issuances will not exceed the number or dollar amount registered and available under the current Registration Statement, will not exceed the number of authorized but unissued shares, and will comply with the limitations of Form S-3 (including General Instruction I.B.6, if applicable).
• Legal Opinion: The company’s counsel, Blank Rome LLP, has issued a legal opinion confirming the validity of the shares to be potentially issued under this agreement. This opinion is filed as Exhibit 5.1 and is incorporated into the report by reference.
• Not an Offer or Solicitation: The company clarifies that this filing does not constitute an offer to sell, nor a solicitation of an offer to buy, any security in any jurisdiction where such offer or sale would be unlawful.
• Exhibits Filed:
  • Exhibit 5.1 – Opinion of Blank Rome LLP
  • Exhibit 10.1 – Original At The Market Offering Agreement (dated June 3, 2025)
  • Exhibit 10.2 – Amendment No. 1 to At The Market Offering Agreement (dated March 25, 2026)
  • Exhibit 23.1 – Consent of Blank Rome LLP (included in Exhibit 5.1)
  • Exhibit 104 – Cover Page Interactive Data File

What Shareholders Need to Know

• Potential for Share Dilution: The amended ATM agreement allows the company to issue additional shares of common stock, which could result in dilution of existing shareholders’ ownership percentages if and when shares are sold.
• Impact on Share Price: Any significant issuance of new shares into the market could potentially exert downward pressure on the company’s share price, depending on the volume and timing of sales and prevailing market conditions.
• Financing Flexibility: The ability to raise capital on an as-needed basis provides Immix Biopharma with added flexibility to fund ongoing operations, pipeline development, and potential future acquisitions or growth initiatives. This may be viewed positively if investors believe the capital will support value-creating activities.
• Emerging Growth Company: Immix Biopharma is classified as an emerging growth company, which may affect certain regulatory and reporting obligations and provides the company with extended transition periods for adopting new accounting standards.
• No Immediate Share Issuance: The filing itself does not mean that shares have been or will be issued immediately; it sets the framework under which shares may be sold in the future, subject to company discretion and market conditions.

Conclusion

This amendment to the ATM Offering Agreement is a material event for shareholders as it provides the company with the capability to raise additional capital efficiently, but it also introduces the potential for future share dilution. Investors should monitor future disclosures to assess how and when the company utilizes this facility, as it can have both strategic benefits and implications for share value.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult their financial advisor before making any investment decisions. The information presented is based on filings made by Immix Biopharma, Inc. and may be subject to change without notice.

View Immix Biopharma, Inc. Historical chart here